Advertisement
Review
The past decade witnessed the rapid development of adult B-lineage acute lymphoblastic leukemia (ALL) treatment. Beyond the development of chemotherapy regimens, immunotherapy is starting a new era with unprec...
Journal of Hematology & Oncology 2017 10:150
Published on: 18 August 2017
Review
Gastric cancer is the third most common cause of cancer death worldwide, although it is not in the top 10 causes of cancer death in Northern America. Due to clear differences in incidence, screening, risk fact...
Journal of Hematology & Oncology 2017 10:149
Published on: 15 August 2017
Research
Structural chromosomal rearrangements that lead to expressed fusion genes are a hallmark of acute lymphoblastic leukemia (ALL). In this study, we performed transcriptome sequencing of 134 primary ALL patient s...
Journal of Hematology & Oncology 2017 10:148
Published on: 14 August 2017
Review
With the development of evidence-based medicine, clinical trials have become necessary for investigating and validating the efficacy of new treatments. Over the past 10 years, several clinical trials of new an...
Journal of Hematology & Oncology 2017 10:147
Published on: 7 August 2017
Review
Gastrointestinal (GI) malignancies are the most prevalent tumors worldwide, with increasing incidence and mortality. Although surgical resection, chemotherapy, radiotherapy, and molecular targeted therapy have...
Journal of Hematology & Oncology 2017 10:146
Published on: 3 August 2017
Review
Spleen tyrosine kinase (Syk) is a cytosolic non-receptor protein tyrosine kinase (PTK) and is mainly expressed in hematopoietic cells. Syk was recognized as a critical element in the B-cell receptor signaling ...
Journal of Hematology & Oncology 2017 10:145
Published on: 28 July 2017
Review
Cancer is caused by uncontrollable growth of neoplastic cells, leading to invasion of adjacent and distant tissues resulting in death. Cancer cells have specific nutrient(s) auxotrophy and have a much higher n...
Journal of Hematology & Oncology 2017 10:144
Published on: 27 July 2017
Erratum
Journal of Hematology & Oncology 2017 10:143
Published on: 27 July 2017
The original article was published in Journal of Hematology & Oncology 2015 8:57
The original article was published in Journal of Hematology & Oncology 2015 8:50
Review
The advent of new immunotherapeutic agents in clinical practice has revolutionized cancer treatment in the past decade, both in oncology and hematology. The transfer of the immunotherapeutic concepts to the tr...
Journal of Hematology & Oncology 2017 10:142
Published on: 25 July 2017
Review
Adaptive immunity is critical for disease progression and modulates T cell (TC) and antigen-presenting cell (APC) functions. Three signals were initially proposed for adaptive immune activation: signal 1 antig...
Journal of Hematology & Oncology 2017 10:141
Published on: 24 July 2017
Research
Understanding the molecular/cellular underpinnings of diffuse malignant peritoneal mesothelioma (DMPM), a fatal malignancy with limited therapeutic options, is of utmost importance for the fruitful management ...
Journal of Hematology & Oncology 2017 10:140
Published on: 17 July 2017
Research
Additional sex combs-like 1 (ASXL1) is frequently mutated in myeloid malignancies. Recent studies showed that hematopoietic-specific deletion of Asxl1 or overexpression of mutant ASXL1
Journal of Hematology & Oncology 2017 10:139
Published on: 11 July 2017
Research
Current conventional chemotherapy for acute myeloid leukemia (AML) can achieve remission in over 70% of patients, but a majority of them will relapse within 5 years despite continued treatment. The relapse is ...
Journal of Hematology & Oncology 2017 10:138
Published on: 11 July 2017
Research
The China Continuation study was a separate regional expansion of the global, double-blind, placebo-controlled, randomized phase III TOURMALINE-MM1 study of ixazomib plus lenalidomide–dexamethasone (Rd) in pat...
Journal of Hematology & Oncology 2017 10:137
Published on: 6 July 2017
Review
Compared to chemotherapy, promising results have been obtained by blocking the PD-1 pathway using antibodies that inhibit programmed cell death protein 1 (PD-1) or programmed cell death protein ligand 1 (PD-L1...
Journal of Hematology & Oncology 2017 10:136
Published on: 5 July 2017
Research
This study compared the effects of pre-transplantation minimal residual disease (pre-MRD) on outcomes in AML patients who underwent human leukocyte antigen-matched sibling donor transplantation (MSDT) or who r...
Journal of Hematology & Oncology 2017 10:134
Published on: 4 July 2017
Research
Granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood stem cells (G-PBSC) has largely replaced unstimulated bone marrow (un-BM) for allografting because of accelerated engraftment, but with ...
Journal of Hematology & Oncology 2017 10:135
Published on: 4 July 2017
Research
UBE2O is proposed as a ubiquitin-conjugating enzyme, but its function was largely unknown.
Journal of Hematology & Oncology 2017 10:132
Published on: 3 July 2017
Review
The two murine double minute (MDM) family members MDM2 and MDMX are at the center of an intense clinical assessment as molecular target for the management of cancer. Indeed, the two proteins act as regulators ...
Journal of Hematology & Oncology 2017 10:133
Published on: 3 July 2017
Research
Particularly since the advent of lenalidomide, lower-risk myelodysplastic syndromes (MDS) patients with del(5q) have been the focus of many studies; however, the impact of age on disease characteristics and re...
Journal of Hematology & Oncology 2017 10:131
Published on: 26 June 2017
Research
Primary refractory acute myeloid leukemia (PRF-AML) is associated with a dismal prognosis. Allogeneic stem cell transplantation (HSCT) in active disease is an alternative therapeutic strategy. The increased av...
Journal of Hematology & Oncology 2017 10:130
Published on: 24 June 2017
Research
The feasibility of cord blood transplantation (CBT) in adults is limited by the relatively low number of hematopoietic stem/progenitor cells contained in one single CB unit. The infusion of two CB units from d...
Journal of Hematology & Oncology 2017 10:128
Published on: 21 June 2017
Research
Protein tyrosine phosphatase receptor gamma (PTPRG) is a ubiquitously expressed member of the protein tyrosine phosphatase family known to act as a tumor suppressor gene in many different neoplasms with mechan...
Journal of Hematology & Oncology 2017 10:129
Published on: 21 June 2017
Research
Despite recent advances in the treatment of multiple myeloma (MM), the prognosis of most patients remains poor, and resistance to traditional and new drugs frequently occurs. EDO-S101 is a novel therapeutic ag...
Journal of Hematology & Oncology 2017 10:127
Published on: 20 June 2017
Rapid communication
MDM2 and CDK4 are frequently co-amplified in well-differentiated/dedifferentiated liposarcoma (WDLPS/DDLPS). We aimed to determine whether combined MDM2/CDK4 targeting is associated wi...
Journal of Hematology & Oncology 2017 10:123
Published on: 19 June 2017
